The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
Part of paid clinical trials in Paramus, New Jersey.
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Study ID
- NCT05419089
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- HPV-positive Oropharyngeal Squamous Cell Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Robotic surgery — PROCEDURETransoral robotic surgical resection of the tumor with negative intraoperative frozen section margins.
Study Details
The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with transoral robotic surgery (TORS) alone can result in cancer control and survival comparable to those previously reported with standard therapy. The protocol includes patients with only with low or intermediate pathologic risk factors following surgery with detectable pre-surgery cfHPVDNA and undetectable post-surgery cfHPVDNA. The hope is that with this approach, the long-term complications from chemotherapy and radiation can be reduced.
Key Dates
- Start date
- Jul 12, 2022
- Status verified
- Jun 2025
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 83 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Robotic surgery only* Complete resection to negative frozen section margins (pT1-2) * \< 4 nodes, ≤ 2 mm extranodal extension (ENE), no supraclavicular nodes
Primary Outcome Measure
Local and/or regional disease recurrence (LRR) [ Time Frame: 2 years ]
Central Contacts
- Mabel Korley(212) 731-3297
- Chanel Rojas(347) 962-6630
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Valley - Mount Sinai Comprehensive Cancer Care | Paramus | New Jersey | 07652 | - |
| Mount Sinai Health System | New York | New York | 10019 | Raymond Chai, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Paramus, NJ
Related Studies
- Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)PHASE2 · Not Yet Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts